Successful Use of Etanercept in a Patient With Pyoderma Gangrenosum Complicating Rheumatoid Arthritis

Disla, Eddys; Quayum, Bhasit; Cuppari, Girolamo; Pancorbo, Roberto

doi:10.1097/01.rhu.0000111315.94725.9c

Cited by 23 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have now been several case reports in the literature of successful treatment of PG using etanercept, regardless of short-term therapy or maintenance treatment. None of these case reports mentioned loss of efficacy during treatment with etanercept (7,(11)(12)(13). Recently, Lecluse et al demonstrated that in patients with psoriasis high titers of antibodies to adalimumab and low adalimumab trough concentrations are associated with poor clinical outcome.…”

Section: Commentmentioning

confidence: 93%

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Kleinpenning

Langewouters

Kerkhof

et al. 2010

Journal of Dermatological Treatment

View full text Add to dashboard Cite

In concordance with previous results of several other studies, reviews and case reports, we presume that possibly both etanercept and adalimumab could be excellent therapeutic alternatives in the treatment of PG. Unfortunately, the effectiveness of both etanercept and adalimumab were very limited in our case. Literature research revealed no other successful studies on the off-label use of other immunomodulators as an alternative treatment option for PG. However, infliximab or ustekinumab could be alternative treatment options.

show abstract

Section: Commentmentioning

confidence: 93%

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Kleinpenning

Langewouters

Kerkhof

et al. 2010

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Etanercept has also been successfully used in some cases of PG without underlying IBD [79,80,81]. In addition, another patient, allergic to infliximab, responded to adalimumab after prior failure of etanercept [82].…”

Section: Discussionmentioning

confidence: 99%

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-α antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn’s-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.

show abstract

“…PG treatment is challenging, whether with topical or systemic immunosuppressive therapies, and skin transplants may be required, although local debridement risks development of pathergy. Whereas a response to methotrexate has been documented in RA patients with PG, treatment with anti‐TNF therapy has been reported to cause PG, prevent its development, or lead to its resolution (35–37).…”

Section: Discussionmentioning

confidence: 99%

High speed multi-level drivers for spectrally efficient optical transmission systems

et al. 2013

View full text Add to dashboard Cite

High spectral efficiency modulation is key to addressing the optical network capacity challenge. Typical implementations of transmitters for advanced modulation formats use high‐resolution silicon digital‐to‐analog converters, complemented by high bandwidth linear amplifiers to drive the electro‐optic modulator. To overcome the limitations of this setup, both in speed and complexity, Bell Labs has proposed and realized an alternative approach based on a multi‐level driver which operates at symbol rates up to 50 GBaud with swings up to 2×2 volts, sufficient to drive various common electro‐optic modulators (Vπ ∼3‐4 V). Over the past two years, multi‐level drivers have enabled various Bell Labs optical system experiments relying on the high signal quality achieved and the rate flexibility offered. The circuit architecture, its main features, and the various system experiments are summarized. © 2013 Alcatel‐Lucent.

show abstract

Successful Use of Etanercept in a Patient With Pyoderma Gangrenosum Complicating Rheumatoid Arthritis

Cited by 23 publications

References 11 publications

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

High speed multi-level drivers for spectrally efficient optical transmission systems

Contact Info

Product

Resources

About